Whitepapers

In this asset, you will discover how the Gibco Efficient-Pro system can revolutionize your mAb manufacturing workflow. It provides insights into optimizing CHO cell productivity, enhancing product titers and protein quality, streamlining process efficiency, and leveraging a reliable supply network.

Download the white paper and learn how Implementing Real-Time Control of Carbon Dioxide can Impact Productivity at R&D and Production Scale Bioreactors. Dissolved CO₂ is a Critical Process Parameter (CPP) in biopharma production processes, as it has a direct impact on product titer and its critical quality attributes. It influences other culture parameters like extracellular and intracellular pH, as well as key performance indicators such as Viable Cell Density. Uncontrolled dissolved carbon dioxide levels in the bioreactor can result in growth inhibition, lower product titer, and decreased product quality.

Download our comprehensive white paper and gain valuable insights into the critical process parameters and advance sensor technologies that can revolutionize your Biopharma Downstream Process (DSP). Discover strategies and techniques to optimize efficiency, improve product quality, and ensure the safety and efficacy of your biopharmaceutical products.

How does PAT apply to the bioreactor? Download our comprehensive white paper and explore what PAT means in Biopharma Upstream processes. Discover cutting-edge solutions to effectively monitor critical process parameters and ensure product quality.

mRNA vaccines and therapeutics continue to reshape medicine, providing unique opportunities to prevent and treat a wide range of diseases. In order to unleash the full potential of mRNA, however, one must consider various factors.

Bio-Rad Laboratories, Inc., Pioneer™ Antibody Discovery Platform helps streamline the phage display-based discovery process and provides researchers with superior identification of high-quality therapeutic antibodies.

Advancements in isothermal amplification technologies are fueling new diagnostic and clinical approaches for pathogen detection and cancer research.

As today’s labs continue to evolve, the software solutions that support them must too. Likewise, laboratory and organization leadership must be open to the advancements available to them from modern technologies. In this white paper, learn how a SaaS-based LIMS modernization program optimizes data management, fosters collaboration, and improves decision-making to stay at the forefront of scientific innovation.

Innovation is the engine that powers a company’s growth and product development, and for enterprises with R&D laboratories, those lab environments are the greatest source of this innovation. In this white paper, learn how a platform approach to scientific data management, including semantic search, advanced analytics, and lab automation, leads to better enterprise decisions at the executive level, optimized lab performance, more discoveries, and stronger product pipelines.

Biopharmaceutical companies are increasingly partnering with CDMOs equipped with technologies and expertise to support analytical testing during process development. The level of complexity required to develop and manufacture cell and gene therapies has increased, including the use of various raw materials, custom reagents, and tailored approaches for managing complex diseases.

Charge heterogeneity is present in most biopharmaceutical protein products. During the manufacturing process, charge heterogeneity of the protein therapeutics can occur due to enzymatic cleavage and chemical post-translational modifications (PTM). For therapeutics like ADCs, not only the antibody contributes to the heterogeneity but also the linker and payload, which add even more complexity to the charge variant profiles. Characterizing the charge heterogeneity of ADCs is essential for critical quality attribute (CQA) assessment to ensure drug safety, efficacy, and potency.

Experience flexibility with TaqMan assays, offering over 2.8 million predesigned options to meet your specific needs.

An intelligent, on-premise platform connecting all the steps of your post-discovery routine qPCR workflows into one single ecosystem. Contact sales for a demo

Innovative qPCR tools for your bioanalysis and quality control. Fast-track your bioanalysis & QC with scalable innovative qPCR tools.

TaqMan SNP Genotyping Assays help you detect and distinguish single-nucleotide polymorphisms (SNPs) accurately and efficiently.

Multiplex better with the newest additions to the TaqMan portfolio

Partnering with a CDMO can help streamline drug development, and certain preparations can help ensure a successful collaboration. Scott Alderucci, Curia’s Director of Process Development, explores the advantages of partnering with a CDMO to navigate the journey from molecule conception to clinical trials, including the expertise, experience, and preparedness that a CDMO brings to the table.

Discover how to accurately analyze purity and impurities, determine sequences, and more with next-generation technologies from Agilent.

Key strategies for accelerating development and manufacturing and development timelines to bring drugs to market faster and give developers a competitive advantage.

Now supplying cleanroom doors, panels and accessories for all cleanroom applications.

The first of its kind prefabricated cleanroom system that integrates with the host facility floor.

Implementing automation involves careful optimization and fine-tuning of various parameters to ensure the accurate execution of cell-based potency assays.

G-CON Clean Solutions has a best in class offering of cleanroom doors, panels and accessories for all cleanroom applications.

A step-by-step path to building confidence in packaging component selection for injectable drugs

Ensure the success of clinical biomanufacturing programs by focusing on key tech transfer practices from the sponsor, commercial, scientific, and program management stakeholders.

Partnering with a CDMO with collective insights and capabilities to support the development and manufacture of an innovative biotherapeutic program is an essential first step to providing better care to patients.